Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
Clinical Trials
Oncolytic Virotherapy
Phase II as Topic
Radiotherapy
Sarcoma
Tumor Biomarkers
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
11
07
2021
entrez:
31
7
2021
pubmed:
1
8
2021
medline:
12
1
2022
Statut:
ppublish
Résumé
Soft-tissue sarcomas (STS) in the extremities and trunk treated with standard-of-care preoperative external beam radiation therapy (EBRT) followed by surgical resection are associated with local and distant relapses. In preclinical studies, oncolytic virotherapy in sarcoma has demonstrated antitumor effects via direct intratumoral oncolysis and cytotoxic T-cell-mediated immune responses. Talimogene laherparepvec (TVEC) is a replication-competent, immune-enhanced, oncolytic herpes simplex virus type 1 engineered for intratumoral injection; it has been approved by the FDA for the treatment of locally advanced and metastatic melanoma. We explored a novel combination of TVEC with standard-of-care EBRT administered preoperatively in patients with locally advanced STS of the extremities and trunk in a phase IB/II clinical trial. Thirty patients with primary STS >5 cm for which EBRT was indicated to achieve negative margins were enrolled. FDA-approved TVEC doses were used. Immune correlative studies in peripheral blood, biopsy and resected tumor tissues were performed. No dose-limiting toxicity was observed. Adverse events were similar to those reported in prior studies with TVEC. One patient with myxoid liposarcoma exhibited a partial response. Seven of the 29 (24%) evaluable patients achieved 95% pathological necrosis. None of the patients developed a herpes infection due to the treatment. Eight of the 29 (27%) patients developed postoperative wound complications, which is consistent with previous studies. None of the patients developed local recurrence after surgical resection of the primary sarcoma. 2-year progression-free and overall survival were 57% and 88%, respectively. Caspase-3 demonstrated increased expression of both in TVEC-treated tissue samples as compared with control samples treated with radiation alone. Preoperative intratumoral TVEC with concurrent EBRT for locally advanced STS is safe and well-tolerated. This combination treatment may enhance immune responses in some cases but did not increase the proposed rate of pathological necrosis. The Caspase-3 biomarker may be associated with a positive effect of TVEC in sarcoma tumor tissue and should be explored in future studies. NCT02453191.
Sections du résumé
BACKGROUND
Soft-tissue sarcomas (STS) in the extremities and trunk treated with standard-of-care preoperative external beam radiation therapy (EBRT) followed by surgical resection are associated with local and distant relapses. In preclinical studies, oncolytic virotherapy in sarcoma has demonstrated antitumor effects via direct intratumoral oncolysis and cytotoxic T-cell-mediated immune responses. Talimogene laherparepvec (TVEC) is a replication-competent, immune-enhanced, oncolytic herpes simplex virus type 1 engineered for intratumoral injection; it has been approved by the FDA for the treatment of locally advanced and metastatic melanoma.
METHODS
We explored a novel combination of TVEC with standard-of-care EBRT administered preoperatively in patients with locally advanced STS of the extremities and trunk in a phase IB/II clinical trial. Thirty patients with primary STS >5 cm for which EBRT was indicated to achieve negative margins were enrolled. FDA-approved TVEC doses were used. Immune correlative studies in peripheral blood, biopsy and resected tumor tissues were performed.
RESULTS
No dose-limiting toxicity was observed. Adverse events were similar to those reported in prior studies with TVEC. One patient with myxoid liposarcoma exhibited a partial response. Seven of the 29 (24%) evaluable patients achieved 95% pathological necrosis. None of the patients developed a herpes infection due to the treatment. Eight of the 29 (27%) patients developed postoperative wound complications, which is consistent with previous studies. None of the patients developed local recurrence after surgical resection of the primary sarcoma. 2-year progression-free and overall survival were 57% and 88%, respectively. Caspase-3 demonstrated increased expression of both in TVEC-treated tissue samples as compared with control samples treated with radiation alone.
CONCLUSION
Preoperative intratumoral TVEC with concurrent EBRT for locally advanced STS is safe and well-tolerated. This combination treatment may enhance immune responses in some cases but did not increase the proposed rate of pathological necrosis. The Caspase-3 biomarker may be associated with a positive effect of TVEC in sarcoma tumor tissue and should be explored in future studies.
TRIAL REGISTRATION NUMBER
NCT02453191.
Identifiants
pubmed: 34330766
pii: jitc-2021-003119
doi: 10.1136/jitc-2021-003119
pmc: PMC8327848
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biological Products
0
talimogene laherparepvec
0
Banques de données
ClinicalTrials.gov
['NCT02453191']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA200673
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA203834
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA260239
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MM has had an advisory role and received research funding from Amgen. VM receives research funding from Amgen.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):637-46
pubmed: 17011442
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Anticancer Res. 2012 Sep;32(9):3911-5
pubmed: 22993336
J Thorac Dis. 2018 Feb;10(Suppl 3):S468-S479
pubmed: 29593892
Iowa Orthop J. 2006;26:154-8
pubmed: 16789469
J Clin Invest. 2018 Apr 2;128(4):1413-1428
pubmed: 29504948
Biology (Basel). 2021 Feb 15;10(2):
pubmed: 33671902
Anticancer Res. 2019 Jul;39(7):3499-3506
pubmed: 31262874
Radiother Oncol. 2005 Apr;75(1):48-53
pubmed: 15948265
Cancer. 2008 Aug 1;113(3):573-81
pubmed: 18521899
Lancet Oncol. 2017 Jun;18(6):812-822
pubmed: 28499583
J Natl Compr Canc Netw. 2014 Apr;12(4):473-83
pubmed: 24717567
Methods Mol Biol. 2015;1219:43-56
pubmed: 25308261
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Eur J Surg Oncol. 2014 Dec;40(12):1671-6
pubmed: 25456440
Eur J Surg Oncol. 2014 Dec;40(12):1641-7
pubmed: 25282099
Ann Surg Oncol. 2010 Oct;17(10):2578-84
pubmed: 20556523
J Clin Oncol. 2009 Dec 1;27(34):5763-71
pubmed: 19884534
Ann Surg Oncol. 2015 Sep;22(9):2824-30
pubmed: 26018726
J Clin Oncol. 2016 Aug 1;34(22):2619-26
pubmed: 27298410
Mol Ther. 2015 Jan;23(1):202-14
pubmed: 25292189
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3678-3687
pubmed: 30733298
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
JAMA Oncol. 2020 Mar 1;6(3):402-408
pubmed: 31971541
Cancer Immunol Immunother. 2017 Jun;66(6):683-695
pubmed: 28238174
BMC Cancer. 2017 Jan 13;17(1):51
pubmed: 28086830
Radiother Oncol. 2011 Jun;99(3):262-70
pubmed: 21704402
Cancer Treat Rev. 2008 Jun;34(4):339-47
pubmed: 18313854
Cell Death Differ. 2001 Feb;8(2):182-91
pubmed: 11313720
Mol Ther Oncolytics. 2018 Nov 06;11:109-121
pubmed: 30569015
Eur J Cancer. 2016 Jan;53:84-95
pubmed: 26700077
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
Int J Oncol. 2010 Dec;37(6):1361-78
pubmed: 21042704
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Mol Ther Oncolytics. 2015 Jan 21;1:14010
pubmed: 27119100
Clin Cancer Res. 2006 Nov 15;12(22):6737-47
pubmed: 17121894
J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):447-53
pubmed: 12218591
Cancer Immun. 2005 Mar 04;5:4
pubmed: 15745419
Cancer Res. 2001 Apr 1;61(7):2953-60
pubmed: 11306473
Clin Cancer Res. 2016 Jul 1;22(13):3127-31
pubmed: 27146699
Clin Cancer Res. 2010 Aug 1;16(15):4005-15
pubmed: 20670951
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846
pubmed: 29420123
Mol Med Rep. 2021 May;23(5):
pubmed: 33649847